• News

RNA Inhibitor Shows Early Efficacy, Safety in Adults With Mixed Dyslipidemia

  • MedPage Today
  • New York, NY
  • (November 15, 2022)

Robert Rosenson, MD, discusses original findings from a double-blind, placebo-controlled phase IIb study evaluating the efficacy and safety of investigational ARO-ANG3, a small interfering RNA inhibitor, in adults with mixed dyslipidemia at the American Heart Association annual meeting.

Learn more